ACCP State of the Union Press Release: Clinical Pharmacists Help Improve Prescription Drug Outcomes

Before President Joe Biden's annual State of the Union address to Congress, ACCP issued a statement calling on the Biden administration and leaders on Capitol Hill to immediately support coverage for comprehensive clinical pharmacy services in Medicare. A copy of ACCP's State of the Union press release is provided below.

Washington, D.C., March 7, 2024 -- In anticipation of President Biden's State of the Union address tonight, the American College of Clinical Pharmacy (ACCP) issued the following statement.

“We applaud President Biden for highlighting health care issues in his State of the Union address. Implementing policies to improve the affordability of healthcare treatments, including prescription drugs, should be a top priority for our Nation’s leaders. Indeed, the cost of pharmaceutical therapies are a top concern for the American public, and President Biden and lawmakers of all ideological stripes should be congratulated for focusing on affordability.”

“However, while it is important to address the cost of prescription drugs, it is equally important -- perhaps even more important -- to ensure that medications are prescribed and utilized safely and effectively. It is a regrettable fact that nearly half a trillion dollars each year is wasted due to ineffective or inappropriate medication use.\(^1\) Our healthcare system, and our Nation, simply can’t afford that any longer.”

“With most medical treatment involving some form of prescription drug therapy, addressing this hugely underappreciated issue could not be more urgent.”

“ACCP represents today’s modern clinical pharmacists – highly skilled healthcare professionals educated and trained as the medication experts in the healthcare ecosystem. Clinical pharmacists routinely work as members of physician-led healthcare teams to ensure that medications achieve their optimal therapeutic benefit. As a result, clinical pharmacists help improve medication treatment and save billions of dollars.”

“Unfortunately, the Medicare program – which pays for the majority of prescribed medications – does not recognize or cover ‘comprehensive clinical pharmacy services’. This is the process of care provided by clinical pharmacists that improves outcomes, optimizes medication use, and saves billions of dollars in Medicare expenses.”

“While addressing prescription drug affordability is extremely important, we urge the President and Congress to immediately support coverage for comprehensive clinical pharmacy services in Medicare.”

ACCP is a professional and scientific society that provides leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in patient care practice and research. ACCP’s membership is composed of more than 17,000 clinical pharmacists, scientists, educators, postgraduate trainees, students, and others who are committed to excellence in clinical pharmacy practice and evidence-based pharmacotherapy.

---

Spring Virtual Town Hall Scheduled for April 3

All ACCP members are invited to attend the College’s spring Town Hall on April 3, 2024, at 5:00 p.m. (CDT). ACCP President Brian Hemstreet will host this virtual Town Hall session, which will provide an opportunity for members to voice questions and comments regarding the College and its activities. Members will also have the opportunity to submit topics in advance for discussion during the Town Hall.

To attend the live Town Hall, members must pre-register in Zoom. Once pre-registered, a link to join the session will come to the registered email address directly from Zoom.

We hope you will consider joining us on April 3. The summer Town Hall session is scheduled for July 9, 2024.

Words Matter: Highlighting an Inclusive Language Resource in ACCP’s DEIA Toolkit

The American Psychological Association Inclusive Language Guide was written to raise awareness, provide direct learning, and support the use of culturally sensitive terms and phrases. The guide includes not only terms and definitions but also explanations regarding why certain terms or phrases are harmful to groups of people who have been marginalized and guidance on avoiding conversational language that may contribute to microaggressions.

The APA Inclusive Language Guide is just one of the more than 100 vetted resources available within ACCP’s Diversity, Equity, Inclusion, and Accessibility (DEIA) toolkit. The toolkit was designed and is maintained by the ACCP DEIA Task Force. The toolkit is available to both members and nonmembers. DEIA resources in the toolkit include those applicable to clinical practice, teaching and education, research and scholarship, mentorship, and recruitment and employment. Search the toolkit for content and/or filter the content by topic, setting, or format. Do you have a resource that would be helpful to others? Please share it with the DEIA Task Force at DEIA@accp.com.

Reference

FIT/MeRIT Applications Accepted Through March 31

ACCP Foundation’s 2024 Focused Investigator Training (FIT) and Mentored Research Investigator Training (MeRIT) programs will be held June 3–7, 2024, on the campus of the University of Nebraska Medical Center College of Pharmacy in Omaha, Nebraska.

FIT is an intensive, 5-day, highly individualized grant optimization program for experienced pharmacist-investigators looking to maximize their chances of success in the current research funding environment.

MeRIT is a 2-year longitudinal program combining in-person and virtual guidance for developing investigators. Beginning with a 5-day immersive experience, participants will be mentored through research question...
and methods design, data collection, results presentation, and manuscript preparation.

For more information about the 2024 FIT and MeRIT programs, or to download an application form, visit the Foundation’s Investigator Development page at www.accpfoundation.org/investigator.

Applications can be submitted through March 31, 2024, and prior submission of a letter of intent is not required to apply. All inquiries about these programs and completed applications should be emailed to Sheldon Holstad at sholstad@accp.com.

2024–2026 NAM Fellowship in Pharmacy – Call for Nominations

The boards of the American College of Clinical Pharmacy and the American Association of Colleges of Pharmacy are pleased to announce the call for nominations for the 2024–2026 National Academy of Medicine (NAM) Fellowship in Pharmacy. The fellowship supports a pharmacist as an early-career health policy or health science scholar. Nominations for the fellowship must be submitted by 3:00 p.m. (ET) on June 3, 2024. Details about the nomination process for the fellowship may be found in the Guide to Nominations section in the text that follows.

The NAM Fellowship in Pharmacy enables talented, early-career health science clinicians, researchers, and scholars to actively participate in the health- and medicine-related work of the National Academies of Sciences, Engineering, and Medicine (National Academies) and to further their careers as future leaders in the field. The NAM Fellowship in Pharmacy is awarded for a 2-year period. During this time, fellows are expected to continue to work at their current institution while being assigned to one of the following health- and medicine-related boards of the National Academies:

- Children, Youth, and Families
- Food and Nutrition
- Global Health
- Health Care Services
- Health Sciences Policy
- Population Health and Public Health Practice

The fellowship requires a 10%–20% time commitment for 2 years, including attendance at a 1-week orientation to health policy, the fall NAM annual meeting, and the meetings of the fellow’s designated board. In addition, the fellow will actively participate in the work of an appropriate expert study committee or roundtable, including contributing to its reports or other products.

This experience will introduce the NAM Fellow in Pharmacy to a variety of experts, including legislators, government officials, industry leaders, executives of voluntary health organizations, scientists, and other health professionals, as well as a variety of perspectives. The fellow will be assigned to an NAM member who will serve as a senior mentor during the 2 years of the fellowship. In addition, the fellow will be provided with a flexible research grant.

The National Academies brings together eminent researchers, policy experts, and clinicians from across the country to provide nonpartisan, scientific, and evidence-based advice to national, state, and local policymakers; academic leaders; health care administrators; and the public. The nominee chosen as fellow will be provided with an exceptional learning environment to develop as a future leader in health care, health policy, and public and global health.

Guide to Nominations

Eligibility Criteria

Nominees for the 2024–2026 NAM Fellowship in Pharmacy must:

- Be nominated by one of the following:
  - A member of NAM
    - Application materials are submitted by the NAM member directly through the NAM portal.
    - This process is encouraged if the candidate has an existing relationship with an NAM member.
    - ACCP and AACP members may also seek organizational endorsement by ACCP or AACP in addition to the NAM member’s nomination by following the respective organization’s application process as outlined below.
  - AACP Board of Directors
    - This process is available to AACP members who do not have an existing relationship with an NAM member. For information on AACP nomination, visit https://www.aacp.org/resource/nam-pharmacy-fellowship.
  - ACCP Board of Regents
    - Application materials are reviewed and evaluated by representatives from the Board of Regents. Successful applications are submitted by ACCP through the NAM portal.
    - This process is available to ACCP members who do not have an existing relationship
with an NAM member. Instructions and contact information are included below.

- Have successfully completed the Pharm.D. degree program of an ACPE-accredited school of pharmacy and/or a Ph.D. degree from a relevant field of study in the pharmaceutical and clinical sciences
- Be able to dedicate 10%–20% of their time to the fellowship for 2 years
- Be 4–10 years after completion of postgraduate work OR 5–15 years after completion of a Pharm.D. degree
- Submit a letter of recommendation from the nominee’s academic department head or equivalent supervisor
- Submit a letter of endorsement by the dean or comparable senior leader
- Be a U.S. citizen or have permanent residency status at the time of nomination

Selection Criteria
Nominees will be evaluated by an NAM-appointed committee on the basis of their professional qualifications, scholarship, and quality of professional accomplishments, as evidenced through publications and research grants, and relevance of current field of expertise to the work of the NAM.

Preference will be given to nominees with a demonstrated interest in and focus on advancing pharmacy practice and scholarship.

Required Materials for ACCP Consideration
- Three letters of recommendation and endorsement from:
  1. Department chair or equivalent supervisor
  2. Academic dean or comparable senior leader
  3. Other individuals familiar with the nominee’s work
- A one-page personal statement describing the nominee’s interest in the program and how the program will further the nominee’s professional development
- An up-to-date curriculum vitae
- A brief, one-page biosketch

All required materials must be submitted by email to kpham@accp.com no later than 3:00 p.m. (ET) on June 3, 2024, for the applicant to be considered by the ACCP Board of Regents for nomination as a fellow for the 2024–2026 program beginning September 1, 2024. For questions about any aspect of the nomination process, please contact Marcia Buck, ACCP Director of Clinical Practice Advancement.

NIH Releases Final Version of COVID-19 Treatment Guidelines

For almost 4 years, the COVID-19 Treatment Guidelines Panel (the Panel) has critically reviewed the growing body of research data on COVID-19 and used that information to develop and revise their recommendations for
Guidelines on the own personal investment strategies and make adjustments, experiencing sustained growth. Much like we assess our profession and ACCP as an organization are navigating market trends, pharmacy as a specialty. The Viral Rebound and Symptom Recurrence guidelines update. Major changes include:

- The Viral Rebound and Symptom Recurrence subsections in Therapeutic Management of Nonhospitalized Adults with COVID-19 and Ritonavir-Boosted Nirmatrelvir (Paxlovid) have been updated with new references. The Panel noted that concerns about the recurrence of symptoms or viral rebound should not be a reason to avoid using antiviral therapy when indicated.

- In Therapeutic Management of Hospitalized Adults with COVID-19, the Panel updated the discussion on the role of remdesivir in adults with COVID-19 who require mechanical ventilation or extracorporeal membrane oxygenation.

- In Therapeutic Management of Nonhospitalized Children with COVID-19, the vaccination status categories that determine a child’s risk level have been revised. Chronic kidney disease and pregnancy were added to the list of risk factors that are associated with progression to severe COVID-19.

For a full list of updates, see What’s New in the Guidelines on the COVID-19 Treatment Guidelines website.

President’s Column
Investing in the Future

Brian Hemstreet, Pharm.D., FCCP, BCP5

I hope your 2024 is off to a great start. As we enter everyone’s “favorite” time of the year, tax season, many of us are assessing and reflecting on our current and future investments, with hopes of experiencing sustained growth. Much like we assess our own personal investment strategies and make adjustments on the basis of market trends, pharmacy as a profession and ACCP as an organization are navigating current trends that may significantly affect the continued growth of clinical pharmacy practice, education, and research. As we work this year toward updating the current ACCP strategic plan, a core component of this process will be assessing current environmental trends and determining where we should invest our time, resources, and member expertise to address the critical issues facing the organization. An area I am passionate about, and one that ACCP and its members can significantly influence, is the development of the next generation of clinical pharmacists who will ultimately sustain the College’s future efforts.

Although ACCP’s focus on developing future clinical pharmacists has not largely involved initiatives targeted toward undergraduate college students, the future of health care training will be influenced by the trend of fewer high school students choosing to go to college. This is compounded by the impact of the much lower-than-projected number of high school graduates anticipated over the next 10 years. According to the American Association of Colleges of Pharmacy year-end report from PharmCAS (Pharmacy College Application Service), the 2022–2023 admission cycle saw the lowest number of applications to pharmacy schools and colleges in the past 20 years. This has resulted in a highly competitive environment among schools and colleges for the recruitment of prospective student pharmacists. Given these trends, investing in students who have chosen a career in pharmacy will be critical for ensuring we develop the next generation of clinicians, educators, and researchers.

Over the past 10 years, ACCP has invested significantly in fostering the professional development of the College’s student members. As ACCP members, you also play a critical role in encouraging student pharmacists to be actively involved in their local and regional student chapters, attending annual ACCP meetings, participating in the Clinical Pharmacy Challenge and Clinical Research Challenge, and taking advantage of the excellent educational and professional development opportunities ACCP offers (https://www.accp.com/stunet/). Given the many ACCP members involved in innovative clinical pharmacy practice and research, taking the opportunity to speak with current or prospective students about your respective career pathway will help students plan their own path to professional success.

I am proud of ACCP’s efforts to reduce barriers to student pharmacist participation in the organization, including the provision of travel awards, access to various webinars, and the open access virtual residency and fellowship showcase offered in conjunction with SNPhA (Student National Pharmaceutical Association) in October 2023. Student pharmacists are experiencing...
more challenges than ever in maintaining ongoing organizational engagement, and these efforts speak to our commitment to supporting their professional development.

Over the past several months, I have had the opportunity to meet many of our highly engaged student members, including those serving on the National Student Network Advisory Committee, those participating in the ACCP Professional Leadership APPE, and the many who presented their research at the 2023 ACCP Annual Meeting in Dallas, Texas. I am greatly inspired by these future clinical pharmacists and ask that you invest whatever time and energy you can to support their advancement and active participation as members of the College. However, our investments shouldn’t stop with student pharmacist members. Our residents, fellows, graduate students, and early career members also need continued support and opportunities in order to experience sustained professional growth. ACCP has continued to respond to these needs by investing in many programs and initiatives to support trainee and early career development programs focused on practice, research, education, and leadership and management. I continue to be impressed by the quality of these programs and thank the ACCP members who have invested their time serving as program faculty, mentors, and supporters.

As we continue to forge ahead in 2024 and rise to the challenges facing ACCP and our profession, regardless of your roles in the College or your workplace, look for opportunities to invest in our student, postgraduate trainee, and early career ACCP members. With your collective efforts, we can contribute to developing and sustaining the next generation of clinical pharmacists. Ultimately, our investment strategy should pay dividends by creating lifelong ACCP members. Thank you again for your support of ACCP – and may your tax season be filled with refunds!

2024 ACCP Clinical Research Challenge: Round 2 Letter of Intent Submission Underway

ACCP is pleased to announce that competition is underway in the Clinical Research Challenge (CRC). Research and scholarship contributes to improved health outcomes for patients and advances in the profession of clinical pharmacy. Critically evaluating and applying primary literature is an essential skill for students pursuing a career in clinical pharmacy. This innovative and unique competition offers teams of three students (those in the first 2 professional years of their degree program) the opportunity to compete and advance through three rounds of competition. The competition began February 12 with 82 teams participating in round 1: The Online Journal Club. Round 1 was based on the following literature:

Teams achieving the top 40 scores advanced to round 2: Letter of Intent (LOI) Submission. These teams were given a clinically focused research question with 2½ weeks to develop and submit a letter of intent following the criteria outlined here. The LOI submissions were due March 1, 2024, and are currently under evaluation by the CRC Oversight, Journal Club, and Review panels. Teams advancing to round 3 will be announced March 25. To view a list of teams participating in each round of the competition, click here.

Please join ACCP in recognizing and thanking the members of the Oversight, Journal Club, and Review panels for their contributions and service to the College in advancing this important program for student members.

2024 CRC Oversight Panel
- Sandra Benavides, Pharm.D., FCCP
- Doug Fish, Pharm.D., FCCP, BCPS-AQ ID
- Anne Hume, Pharm.D., FCCP, BCPS
- Irene La-Beck, Pharm.D.
- Beth Phillips, Pharm.D., FCCP, BCPS
- Tiffany Pon, Pharm.D., BCPS

2024 Journal Club Review Panel
- Allison Bernknopf, Pharm.D., BCPS
- Miki Goldwire, Pharm.D., M.S., M.A., BCPS

2024 CRC Review Panel
- Scott Benken, Pharm.D., BCPS
- Brooke Bernhardt, Pharm.D., FCCP, BCOP, BCPPS
- Jacob Brown, Pharm.D.
- Brooke Buffat, Pharm.D., BCPS
- Kyle Burghardt, Pharm.D.
- Daniel Crona, Pharm.D., Ph.D.
- Robert Di Domenico, Pharm.D., FCCP
- Abigail Elmes, Pharm.D., MHPE, BCPS
- Erika Ernst, Pharm.D., FCCP, BCPS
- Stephanie Flowers, Pharm.D., Ph.D.
- James Hoehns, Pharm.D., FCCP, BCPS
- Abbie Leino, Pharm.D., BCPS
- Gregory Malat, Pharm.D., BCPS
- Tien Ng, Pharm.D., FCCP, BCPS
- Phillip Rodgers, Pharm.D., FCCP, BCPS


2024 ACCP Clinical Pharmacy Challenge: Are You Ready?
Online Team Registration Open; Local Competition Exam Available

ACCP’s novel pharmacy student team competition returns for its 12th season. The ACCP Clinical Pharmacy Challenge offers eligible teams the opportunity to compete in up to four online rounds, with the top eight teams advancing to the live quarterfinal competition at the ACCP Annual Meeting in Phoenix, Arizona, October 12–15, 2024. Team registration for the 2024 Challenge is now available online. Plan now to participate this fall.

Competition Overview
The ACCP Clinical Pharmacy Challenge is a team-based competition in which teams of three students compete against teams from other schools and colleges of pharmacy in a “quiz bowl”-type format. Only one team per institution can enter the competition. Institutions with branch campuses, distance satellites, and/or several interested teams are encouraged to conduct a local competition. ACCP provides a local competition exam that institutions may use in selecting their team. Faculty members interested in using the exam may send an email request to Michelle Kucera, Pharm.D., BCPS, at mkucera@accp.com.

Preliminary rounds of the 2024 national competition will be conducted virtually in August and September. The quarterfinal, semifinal, and final rounds will be held live at the ACCP Annual Meeting in Phoenix.

Each round will consist of questions offered in the three distinct segments indicated below. Item content used in each segment has been developed and reviewed by an expert panel of clinical pharmacy practitioners and educators.
- Trivia/Lightning
- Clinical Case
- Jeopardy-style


Each team advancing to the quarterfinal round held at the 2024 ACCP Annual Meeting will receive three complimentary student full-meeting registrations. Each team member will receive an ACCP gift certificate for $125 and a certificate of recognition. In addition, semifinal teams not advancing to the final round will receive a semifinal team plaque for display at their institution. The second-place team will receive a $750 cash award ($250 to each member) and a commemorative team plaque. The winning team will receive a $1500 cash award ($500 to each member), and each team member will receive a commemorative plaque. A team trophy will be awarded to the winning institution.

Students are not required to be members of ACCP to participate. Team registration can be submitted online and must be initiated by a current faculty member at the respective institution. Students interested in forming a team should contact their ACCP faculty liaison. If no ACCP faculty liaison has been identified, any faculty member from the institution may initiate the registration process. The registering faculty member must confirm the eligibility of all team members and/or alternates online before a team will be permitted to compete in the Clinical Pharmacy Challenge. The deadline to complete team registration and confirm eligibility for the 2024 competition is September 3, 2024.

For more information on the ACCP Clinical Pharmacy Challenge, including the competition schedule, sample items, and FAQ section, click here.

2024 ACCP Annual Meeting Call for Abstracts
October 12–15, Phoenix, Arizona

Important Dates:
- Submission Deadlines
  - June 15, 2024: Submission deadline for Original Research, Systematic Reviews/Meta-Analyses, Scoping Reviews, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts
  - August 15, 2024: Submission deadline for Research-in-Progress abstracts (Students and Residents and Fellows, only)

- Notifications of Acceptance
  - August 15, 2024: Authors of Original Research, Systematic Reviews/Meta-Analyses, Scoping Reviews, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts will be notified of acceptance or declination no later than this date.
  - September 1, 2024: Authors of Research-in-Progress (Students, Residents, and Fellows, only) abstracts will be notified of acceptance or declination no later than this date.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit https://www.accp.com/abstracts/2024abstracts on the ACCP website. Note: Scoping Reviews is a new abstract category for the 2024 ACCP Annual Meeting. If you are interested in submitting a Scoping Review, please carefully review the evaluation criteria before submission.

All abstracts accepted and presented by the designated presenting author, except for “Encore,” “Research-in-Progress,” and PRN Contributed presentations, will have full-text abstracts published online in JACCP, an official journal of ACCP. Only the abstract title, authors, and original citation will be published for “Encore” presentations. All accepted abstracts will be published full text in the ACCP meeting app.

Abstract Categories:
Advances in International Clinical Pharmacy Practice, Education, or Training: Abstracts must describe the delivery, justification, documentation, and significance of clinical pharmacy practice, education, or training outside the United States. Abstracts may be descriptive and need not contain an evaluative component.
Case Reports: Abstracts of case reports must update and expand therapeutic insights and possibilities or generate research hypotheses. Although narrative in nature, these abstracts must stress the “evidence” for the authors’ conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient’s case, how the patient was evaluated and treated, and a specific description of the outcome. Encore submissions are also welcome.

Clinical Pharmacy Forum: Abstracts must describe the delivery, justification, documentation, adaptability, and impact/significance of innovative clinical pharmacy services. Abstracts that address CMM (comprehensive medication management) implementation (see www.accp.com/cmm), address components of the ACCP Standards of Practice for Clinical Pharmacists, and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.

Original Research: Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should be relevant to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are invited. Encore submissions are also welcome.

Scoping Reviews: Abstracts must describe a scoping review adhering to the guidelines established by PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Submissions should highlight the objectives, findings, and implications of the review, emphasizing its contribution to knowledge and identifying gaps for further research. (Note: Scoping Reviews are distinct from traditional literature reviews in their broader focus and exploratory nature.)

Systematic Reviews/Meta-Analyses: Abstracts must describe a systematic review adhering to the guidelines and definitions established by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and include the 12 items published in the PRISMA for Abstracts checklist. Encore submissions are also welcome. (Note: Systematic Reviews are not the same as a literature review.)

Residents and Fellows Research-in-Progress: Submission guidelines are the same as for an Original Research abstract except that the research effort is ongoing at the time of abstract submission. The presenting author must be in a postgraduate training program (PGY1 or PGY2 residency, Ph.D./master’s graduate degree program, or fellowship training program).

Students Research-in-Progress: Submission guidelines are the same as for an Original Research abstract, except that the research effort is ongoing at the time of abstract submission. The presenting author must be a first professional degree (Pharm.D. or BSPharm) student.

Encore Presentations: Submission and evaluation criteria are the same as for the Original Research, Systematic Reviews/Meta-Analyses, and Case Reports categories, except that the same abstract was presented elsewhere or published in abstract form only before this meeting. Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change but must be an author on the original abstract.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit https://www.accp.com/abstracts/2023abstracts/ on the ACCP website.

UPCOMING EVENTS & DEADLINES:

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024 Virtual Poster Symposium: Abstract Submission Deadline (Except Research-in-Progress)</td>
<td>March 25, 2024</td>
</tr>
<tr>
<td>Spring Member Town Hall</td>
<td>April 3, 2024</td>
</tr>
<tr>
<td>2024 Emerge From the Crowd</td>
<td>April 6, 2024</td>
</tr>
<tr>
<td>2024 Virtual Poster Symposium: Research-in-Progress Abstract Submission Deadline</td>
<td>April 22, 2024</td>
</tr>
</tbody>
</table>
Since October 2023, Wasem Gawish, D.Ph., BCPS, BCMTMS, has been working in a congressional office on Capitol Hill in Washington, D.C., as the 2023–2024 American College of Clinical Pharmacy/American Society of Health-System Pharmacists/Virginia Commonwealth University Congressional Healthcare Policy Fellow.

Gawish is serving in the office of Senator Martin Heinrich (D-NM). First elected to the Senate in 2012 after serving in the House of Representatives, Heinrich holds a position on the powerful Senate Appropriations Committee and chairs the bipartisan Senate Artificial Intelligence Caucus.

Midway through his Fellow year, Gawish sat down with ACCP staff to discuss his experience so far.

How did you first become interested in politics?
My interest in politics stemmed from a desire to make impactful changes in health care policy. I realized that policymaking is a key tool that can be used to shape and improve health outcomes. Upon meeting Dr. Kristin Zimmerman at Midyear in 2022 and learning about the ACCP/ASHP/VCU Congressional Fellowship, I knew it was the right opportunity for me and immediately applied.

How do you like living in Washington, D.C.?
Living in Washington, D.C., has been an enlightening experience. Being at the center of the nation’s political scene has allowed me to participate directly in policymaking. Not to mention, D.C. is a city brimming with museums and historical landmarks, which further enhances the enriching experience that the fellowship offers.

What has surprised you about working in a congressional office?
What has surprised me the most about working in a congressional office is the complexity of the legislative process. It demands significant collaboration, negotiation, and strategic planning. Furthermore, I was pleasantly surprised to find that policymakers highly value our real-world experience as pharmacists. The significance of our contribution to the legislative process cannot be overstated.

How much of your time do you spend working on pharmacy issues?
As a health and health AI policy fellow, a significant portion of my time is spent on pharmacy issues because it is one of the key areas in health care policy.

What are your plans for after the Fellow Program? Do you think you’ll stay in the D.C. area?
After the Fellow Program, I plan to continue working in health policy. Whether I’ll stay in the D.C. area will largely depend on where the best opportunities to make an impact are.
Gawish spoke passionately about his work in Congress and this unique opportunity to share policy that helps improve how pharmacists take care of patients. In particular, Gawish highlighted a letter Heinrich recently sent to FDA Commissioner Robert Califf, requesting that medications for opioid use disorder (MOUD), including buprenorphine and methadone, be added to the FDA’s List of Essential Medicines. The letter specifically notes that despite the proven effectiveness of MOUD, many hospitals and EDs do not include MOUD in their formularies. This exclusion poses a significant challenge in inpatient settings, particularly for providers who need to initiate MOUD in new patients with opioid use disorder during their hospital stay. In addition, gaps in treatment through MOUD can notably increase overdose risks and fatalities. Click here to read Heinrich’s letter to the FDA.

About the Healthcare Policy Fellow Program
For almost 20 years, this prestigious program has offered a unique, year-long health care policy learning experience in the U.S. Congress. This provides pharmacists an opportunity to gain insight into health care policy analysis and development through immersion in the congressional environment. The Fellow Program begins in July with an immersive orientation in health policy across 3 weeks each with ACCP’s and ASHP’s government affairs offices, followed by 12 months on Capitol Hill.

Alumni Fellows
After serving in the program, past fellows have gone on to engage in a variety of important roles in health care policy and government:

- Amanda Ferguson, Pharm.D., the 2022–2023 fellow, served as a health policy specialist on the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP).
- Tatiana Bujnoch, Pharm.D., M.S., BCPS, currently serves as Health Equity and Policy Associate at Morgan Health.
- Nimit Jindal, Pharm.D., currently serves as Senior Health Policy Advisor, U.S. Senate Committee on Health, Education, Labor and Pensions (HELP).
- Rita (Habib) Livadas, Pharm.D., currently serves as Director, Global Public Health, Life Sciences at Becton, Dickinson and Co.

Applications for the 2025–2026 Pharmacy Healthcare Policy Fellow Program
Interested candidates should visit the pharmacy Congressional Healthcare Policy Fellow program website for more information and instructions on submitting an application. For more information, click here.

PRNs Invited to Present a Poster at the Annual Meeting
ACCP PRNs are invited to submit abstracts for posters to be presented at the 2024 ACCP Annual Meeting in Phoenix, Arizona, October 12–15, 2024. Abstracts with a maximum of 300 words are welcome. Abstracts can be descriptive in nature and do not necessarily need to contain an evaluative component. The PRN Contributed Posters category offers an opportunity to present various PRN member development events, grants, scholarships or awards, position paper development efforts, or other PRN activities of interest to other PRNs or ACCP members in general.

Abstracts will not be peer-reviewed. One submission per PRN is allowed, and the deadline for abstract submission is September 1, 2024. Click here to submit an abstract.

Member Recruiters
Many thanks to the following individuals for recruiting colleagues to join them as ACCP members:

Christina Aquilante, Kyle Brown, Joseph Fava, Holly Gagnon, Patricia Kokoski, Natalie Koussa, Emily Nemire, Kelly Rogers, Krisy Thornby, Rebecca Tran, Justin Wilder, Eric Wright
| Title: Clinical Pharmacist Specialist - General Pediatrics | Learn More |
| Employer: Nicklaus Children’s Health System | |
| Location: Miami, Florida | |

| Title: Clinical Pharmacy Specialist | Learn More |
| Employer: Luminis Health | |
| Location: Lanham, Maryland | |

| Title: Assistant/Associate Professor – Psychiatry | Learn More |
| Employer: Western University of Health Sciences, College of Pharmacy | |
| Location: Pomona, California | |

| Title: Assistant/Associate Professor – Acute Care Medicine (Any Specialty) | Learn More |
| Employer: Western University of Health Sciences, College of Pharmacy | |
| Location: Pomona, California | |

| Title: Assistant/Associate/Professor of Clinical Pharmacy – Oncology/Immunology (Clinical Track) | Learn More |
| Employer: USC | |
| Location: Los Angeles, California | |

| Title: Chair, Department of Pharmacy Practice and Administration | Learn More |
| Employer: St. John Fisher College | |
| Location: Rochester, New York | |
Featured Positions

Title: Pharmacy Clinical Specialist - Ambulatory Complex Care
Employer: Cincinnati Children’s Hospital Medical Center
Location: Cincinnati, Ohio

Title: Advanced Practice Pharmacists
Employer: Sutter Health
Location: Multiple Locations in Northern California

Title: Clinical Pharmacy Specialist - Hematology-Anticoagulation Stewardship
Employer: Memorial Hermann
Location: Houston, Texas

Title: Assistant or Associate Professor of Pharmacy Practice
Employer: Jefferson College of Pharmacy
Location: Philadelphia, Pennsylvania

Title: Visiting Clinical Assistant Professor/Visiting Clinical Pharmacist
Employer: UIC
Location: Chicago, Illinois

Title: Clinical Pharmacist Specialist, Emergency Medicine
Employer: Endeavor Health Edward Hospital
Location: Naperville, Illinois
Featured Positions

Title: Clinical Pharmacy Specialist - Neurocritical Care  
Employer: Trinity Health Ann Arbor  
Location: Ann Arbor, Michigan  

Title: Assistant/Associate Professor in Ambulatory Care  
Employer: Medical College of Wisconsin School of Pharmacy  
Location: Milwaukee, Wisconsin